Dianthus Therapeutics, Inc. (DNTH) stock forecast and price target
Price $91.81 · data as of November 13, 2026
12-month price target
Average target$139.25
Upside / downside+51.7%
Analysts16
ConsensusStrong buy
Low $113.00Average $139.25High $200.00
Gold marker: average target · white marker: today’s price ($91.81)
Analyst ratings
Strong buy 1Buy 17Hold 0Sell 0Strong sell 0
Earnings and revenue estimates
| Period | EPS estimate | EPS growth | Revenue estimate |
|---|---|---|---|
| Current fiscal year ends December 31, 2026 | $-3.60 | +14.3% | $3M |
| Next fiscal year ends December 31, 2027 | $-4.35 | −20.8% | $2M |
| Next quarter ends December 31, 2026 | $-0.99 | +30.5% | $339050 |
| Quarter after ends March 31, 2027 | $-1.03 | −21.5% | $460280 |
Consensus of the analysts covering Dianthus Therapeutics, updated daily. In the last 30 days 4 estimates were raised and 0 lowered.
Frequently asked questions
What is the Dianthus Therapeutics stock price target?
The average 12-month target from 16 analysts is $139.25, 51.7% above the current price of $91.81 Targets range from $113.00 to $200.00.
Is Dianthus Therapeutics a buy according to analysts?
The consensus rating is “Strong buy” (1 strong buy, 17 buy). Ratings are opinions, not guarantees; this is not investment advice.
How much is Dianthus Therapeutics expected to earn?
Analysts expect EPS of $-3.60 for the fiscal year ending December 31, 2026 and $-4.35 the year after.
Analyst consensus estimates and price targets, updated daily. Forecasts can be wrong; this is information, not investment advice.